Enara Bio
Enara Bio is a biopharmaceutical company that develops cancer immunotherapies by targeting Dark Antigens derived from genomic dark matter. The company utilizes its EDAPT platform to discover these novel antigens and its EnTiCE platform to develop bispecific T-cell engagers for the treatment of solid tumors. Its lead program, ENA101, is a T-cell engager targeting the DARKFOX antigen for broad patient populations.
Visit websiteOxford, UK
Biotechnology
Biopharmaceuticals
Oncology
Immunotherapy
Funding summary
- Total raised
- €29.4M
- Funding rounds
- 1
Investors in Enara Bio
Investors on record for Enara Bio. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Enara Bio?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors